MedTrace Logo

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA

NCT01694758 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 733

Last updated 2014-08-15

No results posted yet for this study

Summary

OPTIMISE-CEEMEA is a multinational, multi-centre, observational, prospective study which will include patients suffering from diabetes type 2, treated or untreated, insulin dependent or not insulin dependent.

In this study we aim to explore at a primary care level whether the use of benchmarking against a set of guideline-based reference values on a patient basis, may improve quality of patient care, in particular control of diabetes, lipids and blood pressure.

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent

Sponsors & Collaborators

Principal Investigators

  • Dan Isacoff, ASSOC. PROF. · University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Bulgaria
  • Romania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01694758 on ClinicalTrials.gov